Concepedia

Federico Cappuzzo

FC

Statistics

Publications

199

Citations

41.3K

H-Index

84

Active since

1995

Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico(Current)

Ospedale di Livorno

Azienda Unità Sanitaria Locale Della Romagna

Fondazione IRCCS Istituto Nazionale dei Tumori

Florida Hospital Cancer Institute

Federico Cappuzzo is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

1995–2025

199

Publications

199

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

, , +17

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.8K citations · Full text

, , +16

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim et al. · New England Journal of Medicine · 2014 · 3.2K citations · Full text

, , +12

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

, , +13

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology · 2019 · 1.7K citations

, , +12

1–5 of 199